International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3044 - 3044
Published: March 26, 2025
B7H3 (CD276), an immunoregulatory molecule known for its role in immune evasion by transmitting inhibitory signals to T lymphocytes, has garnered significant attention recent years as a promising target cancer immunotherapy. This interest is largely due high expression various types of solid tumors, coupled with low protein levels normal tissues. However, studies examining the impact on survival outcomes have shown inconsistent results, leaving prognostic significance not fully clarified. Therefore, this meta-analysis aimed assess relationship between and parameters patients malignancies. PubMed, Web Science (WOS), Cochrane, SCOPUS, Embase databases were searched eligible articles published until November 2024. Statistical analysis was performed using R studio (version 4.3.2). The included total 51 comprising 11,135 patients. Results showed that overexpression negative predictor all examined outcomes: OS (HR = 1.71, 95% CI 1.44-2.03, p < 0.0001), DFS 2.02, 1.49-2.73, PFS 2.10, 1.44-3.06, RFS 1.66, 1.11-2.48, 0.01), DSS 1.70, 1.24-2.32, 0.01). Despite heterogeneity observed across studies, sensitivity confirmed robustness these results. research suggests may serve effective biomarker prognosis tumors.
Language: Английский